Pre- and post-natal treatment of hemophagocytic lymphohistiocytosis

Pediatr Blood Cancer. 2009 Jan;52(1):139-42. doi: 10.1002/pbc.21778.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare autosomal recessive disorder of infancy and childhood that is invariably fatal if not treated. We report on the first patient to receive post-natal HSCT for HLH after receiving in utero chemotherapy for disease stabilization.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cognition Disorders
  • Developmental Disabilities
  • Female
  • Fetal Therapies
  • Fetus
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Infant, Newborn
  • Lymphohistiocytosis, Hemophagocytic / diagnosis*
  • Lymphohistiocytosis, Hemophagocytic / physiopathology
  • Lymphohistiocytosis, Hemophagocytic / therapy*
  • Pregnancy

Substances

  • Antineoplastic Agents